Reference (passed peer review btw):
Muhammad Salman Hameed, Hongxuan Cao, Li Guo, Lei Zeng, Yanliang Ren, Advancements, challenges, and future frontiers in covalent inhibitors and covalent drugs: A review, European Journal of Medicinal Chemistry Reports, Volume 12, 2024, 100217, ISSN 2772-4174, https://doi.org/10.1016/j.ejmcr.2024.100217
Try this link if the above doesn’t work (not that it’s worth visiting in the first place…): https://www.sciencedirect.com/science/article/pii/S277241742400089X?via%3Dihub
“I have lung cancer? How bad is it?”
“Well let’s just say it’s…non-small lung cancer.”
I just want to see the tiny cars
Looks like non-small lurrIb cancer to me
Actually that part is a legitimate classification and not part of the AI nonsense. Broadly, lung cancers are classified as either “small cell” cancers or “non small cell” cancers based on how the tumor appears microscopically. The “non small cell” cancers can be further subdivided into various types.
The reason for this distinction between the two is due to the significant difference in clinical management and prognosis. Having “small cell” lung cancer is effectively a death sentence, whereas the other types are a lot more treatable.